BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Vertex Pharmaceuticals Stock Plunges After Clinical Trial Disappointment
Vertex Pharmaceuticals Stock Plunges After Clinical Trial Disappointment
17
3
BTCCSquare news:
Vertex Pharmaceuticals (VRTX 0.23%), once a darling of the pharma sector, faces investor skepticism after its acute pain treatment VX-993 failed to meet primary endpoints in Phase 2 trials. The setback triggered a sharp sell-off, underscoring the high-stakes nature of biotech investing.
The company's recently approved non-opioid painkiller Journavx had fueled Optimism for its pipeline expansion. Yet the latest clinical results reveal the fragility of drug development—even for established players. Market reactions were swift and severe, with no immediate recovery in sight.
By:
